Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic dru...

全面介紹

書目詳細資料

Principais autores:	Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel
格式:	Artigo
語言:	Inglês
出版:	Wiley 2026-04-01
叢編:	Annals of Clinical and Translational Neurology
主題:	complement inhibition complement pathway eculizumab myasthenia gravis ravulizumab
在線閱讀:	https://doi.org/10.1002/acn3.70251
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!